Elenco degli articoli con argomento «micosi fungoide»
Dermatologia20 feb 2024
Clinicopathological definition, management and prognostic value of mogamulizumab
Mogamulizumab is a first-in-class IgG1k monoclonal antibody that selectively targets the chemokine receptor type 4
23 nov 2023
EORTC consensus recommendations
On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and following up on earlier versions published in 2006 and 2017
03 lug 2023
Prevalence and Implications of Mogamulizumab-induced Immune
Prevalence and Implications of Mogamulizumab-induced Immune
17 apr 2023
Multidisciplinary Approach to the Diagnosis
Mycosis fungoides is the most common primary cutaneous T-cell lymphoma
28 nov 2022
Folliculotropic Mycosis Fungoides
Folliculotropic mycosis fungoides (FMF) is the most frequent variant of mycosis fungoides
04 lug 2022
Dermoscopic spectrum of mycosis fungoides
The dermoscopic features of classic patch stage mycosis fungoides (MF) have been described
02 ago 2021
Disease characteristics, prognosis, and response to therapy in patients
Mycosis fungoides with large cell transformation (MF-LCT) is associated with an aggressive clinical course yet data comparing treatment outcomes in MF-LCT are sparse.
10 mag 2021
Treatment of early-stage mycosis fungoides
The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI)
10 mag 2021
Mycosis Fungoides in Children and Adolescents
Comprehensive data on childhood mycosis fungoides (MF) is scarce.
10 mar 2021
Dermoscopy of Syringotropic and Folliculotropic
Dermoscopy of Syringotropic and Folliculotropic Mycosis Fungoides
15 feb 2021
Treatment of Mycosis Fungoides
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL).
04 feb 2021
Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides
Italian expert-based recommendations on the use of photo(chemo)therapy
26 gen 2021
Gender differences in clinical presentation, treatment, and outcomes in mycosis fungoides
Mycosis fungoides (MF) comprises 54% of cutaneous T cell lymphomas. Although the etiology is unknown, prior studies have shown that MF is more common in males than females, with greater incidence in African Americans (AAs).
30 ago 2020
Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides?
Results from the PROCLIPI international Study
11 nov 2019
Poikilodermatous plaque-like hemangioma: Case series of a newly defined entity
We present a distinctive type of acquired vascular proliferation, for which we propose the name of poikilodermatous plaque-like hemangioma.
16 gen 2019
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia.
Brentuximab Vedotin (BV, SNG35) is an antibody drug-conjugated against CD30 molecule.
08 mag 2014
Candida, colpisce 7 donne su 10. E molte rinunciano al sesso
Ci fanno i conti il 28% delle adolescenti e il 25% delle mamme in dolce attesa. I sintomi sono prurito, dolore e perdite. Sei regole per prevenire le ricadute
08 dic 2012
Insidie a fior di pelle per i frequentatori delle palestre
Irritazioni e micosi sono diffuse tra gli sportivi. Per ridurre il rischio bastano semplici accorgimenti
09 gen 2011
Studio su larga scala su efficacia di differenti modalità di foto(chemio) terapia nel trattamento di psoriasi, vitiligine e micosi fungoide
La psoriasi, la vitiligine e la micosi fungoide sono tra le malattia dermatologiche più frequentemente trattate con la foto (chemio) terapia. Lo scopo di questo lavoro è quello di determinare quali modalità terapeutiche possono dare i migliori risultati nel trattamento di queste malattie
02 ott 2005
Trapianto allogenico di cellule staminali
Al momento attuale, accanto a nuove molecole come bexarotene, denileukin diftitox e alemtuzumab, si sta valutando l'impiego del trapianto allogenico di cellule staminali, anche se, le esperienze sono ancora limitate